Oncology

Latest News

In the phase 3 IMforte trial, patients with extensive-stage small cell lung cancer experienced clinically meaningful benefits with maintenance lurbinectedin plus atezolizumab vs atezolizumab. | Image credit: appledesign - stock.adobe.com

Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

By Rose McNulty

May 22nd 2025

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.

AJMC Q&A with Eileen Peng, PharmD | Background image credit: ipopba - stock.adobe.com

The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

By Laura Joszt, MA
Eileen Peng, PharmD

May 21st 2025

Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com

Novel, Noninvasive Skin Cancer Detection Method Shows Promise

By Jared Kaltwasser

May 18th 2025

FDA Approved | Image credit: chrisdorney – stock.adobe.com

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

By Hayden E. Klein

May 14th 2025

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com

Flow Cytometry Can Reliably Identify CTC in Melanoma

By AJMC Contributor

May 14th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

August 12th 2015

The Need to Eliminate Barriers to Personalized Medicine

Alan Balch, PhD

Precision medicine will perhaps establish some of the most important biomedical innovations of our generation. However, for that future to become a reality, we have to create an access and reimbursement environment that is conducive to precision care.

August 12th 2015

Myriad's New CEO Discusses Promise, Challenges of Changing Times in Genetic Testing

Mary K. Caffrey

Evidence-Based Oncology spoke with Mark Capone about the challenges and opportunities in molecular diagnostics, and what's ahead at Myriad Genetics.

August 12th 2015

The Vision of an Effective and Equitable Future for Personalized Medicine

Joseph Alvarnas, MD

In his editorial piece, Joseph Alvarnas, MD, narrates the importance of precision medicine in oncology care.

August 12th 2015

Need for Consistency in Radiation Treatment Costs Among Medicare Enrollees

Surabhi Dangi-Garimella, PhD

Research published in the Journal of Oncology Practice found that factors unrelated to the individual patient accounted for the majority of variation in the cost of radiation therapy for breast, prostate, and lung cancer patients.

August 11th 2015

Risk Stratification Could Improve Precision in Colon Cancer Screening

Surabhi Dangi-Garimella, PhD

A novel risk-stratification index can help avoid unnecessary colonoscopies in individuals at low-risk for developing colorectal cancer.

August 10th 2015

Noninvasive Technique Could Allow Earlier Intervention and Improve Outcomes in Pediatric Medulloblastoma

Surabhi Dangi-Garimella, PhD

A collaborative research study has discovered the effective use of magnetic resonance spectroscopy in the noninvasive diagnosis and molecular characterization of brain tumors in children.

August 10th 2015

Blinatumomab Wins CMS Favor Following Reevaluation

An immunotherapy developed by Amgen and approved by the FDA for the treatment of acute lymhoblastic leukemia in December 2014 has now received coverage assurance from Medicare, following an initial rejection.

August 10th 2015

Personalized Medicine: On the Brink of Revolutionizing Cancer Care

Sean Khozin, MD, MPH Gideon Blumenthal, MD

With unprecedented activity in the area of precision medicine, with the successful development of several targeted therapies, the FDA has been in the forefront of efforts to ensure timely access to, and the safe and effective use of, these therapies.

August 10th 2015

Equalize Payment Across Site of Service

Barry Brooks, MD

For many US community cancer centers, keeping the doors open has often meant making the difficult decision to consolidate with hospitals and large hospital systems. Site neutrality is a critical step in the journey toward better healthcare for all Americans and a healthy future for Medicare.

August 7th 2015

Alternative Payment Models: Paving the Way or Building a Wall for Personalized Medicine?

Amy M. Miller, PhD Andrew J. Shin, JD, MPH

As personalized medicine rapidly becomes an effective tool for combating cancer, payers are exploring new, value-based payment paradigms. These trends will soon intersect, and depending on how they are structured, the new payment models could accelerate or stifle personalized medicine's progress.

August 6th 2015

CHAARTED Study: Conceptual Shift in Early Prostate Cancer Treatment

Surabhi Dangi-Garimella, PhD

Results from the CHAARTED trial have found that 6 cycles of chemotherapy combined with ADT early in the treatment of metastatic prostate cancer significantly improved overall survival than with ADT alone.

August 5th 2015

Chemoprevention With Oral Contraceptives Could Be a Reality

Surabhi Dangi-Garimella, PhD

A retrospective study in The Lancet Oncology has identified a strong correlation between reduced risk of endometrial cancer and oral contraceptive agents.

August 5th 2015

Balancing Innovation With Cost in Diagnostic Testing

Gnanamba Varuni Kondagunta, MD

As clinical targets in more common malignancies emerge, testing and treatment options will increase. Balancing these choices with the high costs of new technology will be the challenge to ensure value in oncology care.

August 5th 2015

Next-Generation Sequencing: Are We There Yet?

Surabhi Dangi-Garimella, PhD

While scientists agree that NGS is the way of the future, payers are as yet apprehensive on the value afforded by the tests to clinical decisions.

August 4th 2015

Precision Oncology: Are Payers on the Right Pathway?

Jerry Conway Mark Oldroyd, JD

In oncology, the shift from a "companion diagnostic" to a "companion therapeutic" paradigm is in high gear. While the noise and confusion is leading many payers to avoid coverage, they can benefit by proactively taking steps to integrate precision oncology to better manage quality, access, and cost of cancer care.

August 4th 2015

Proteomic Analysis Yields Urine Test for Early Diagnosis of Pancreatic Cancer

Surabhi Dangi-Garimella, PhD

A research team at the Barts Cancer Institute in London has identified a 3-protein molecular signature in pancreatic cancer patients.

August 3rd 2015

Discovery Could Improve Prognosis for Triple Negative Breast Cancer Patients

Surabhi Dangi-Garimella, PhD

The discovery could lead to targeted therapy in triple negative breast cancer patients.

Dr Jennifer Malin Predicts Biosimilars Will Have Little Impact on Treatment Costs

August 3rd 2015

Dr Jennifer Malin Predicts Biosimilars Will Have Little Impact on Treatment Costs

The introduction of biosimilars into the US market will not have a large impact on treatment costs until the volume of biosimiliars for different therapies increases, predicted Jennifer Malin, MD, medical director for oncology at Anthem.

July 31st 2015

A Potential Tool to Predict Recurrence of HPV-Related Oropharyngeal Carcinoma

Surabhi Dangi-Garimella, PhD

A study published in JAMA Oncology presents a new tool that can predict disease recurrence in oropharyngeal cancer patients.

July 30th 2015

New Study Claims Improved Gene Expression-Based Risk Stratification for Prostate Cancer

Surabhi Dangi-Garimella, PhD

Urologists at Cancer Research UK have identified 5 distinct genomic signatures in prostate cancer that can have important implications on treatment decisions.

July 29th 2015

Anti-Inflammatory Agents Improve Outcomes and QOL in Cancer Patients

Surabhi Dangi-Garimella, PhD

New research studies show that anti-inflammatory agents can improve survival as well as quality of life in cancer patients.

July 28th 2015

New Study Could Improve Precision With Pituitary Tumor Excision

Surabhi Dangi-Garimella, PhD

Physicians at the Brigham and Women's Hospital have published results from a proof-of-concept study that used mass spectrometry in almost real-time to detect and delineate pituitary tumors from normal tissue.

July 28th 2015

Two Generics Reduce Breast Cancer Deaths, Studies Find

Laura Joszt, MA

Two inexpensive generic drugs have been shown to reduce breast cancer deaths in postmenopausal women, according to studies published in The Lancet.

July 28th 2015

Electronic Data Share to Improve Cancer Outcomes

Surabhi Dangi-Garimella, PhD

The California Department of Public Health has announced participation in a pilot project with St. Joseph Health to better understand cancer trends in California.

July 27th 2015

Patient-Centered Oncology Care 2015: When Precision Medicine Meets Regulation

Before "value" became a cancer care buzzword, The American Journal of Managed Care was the first to create a conference where stakeholders discussed how to deliver the best care possible-and figure out how to pay for it. The fourth installment of Patient-Centered Oncology Care on November 19-20, 2015, in Baltimore, Maryland, will address the regulation of molecular diagnostics and ongoing efforts at payment reform.

This Week in Managed Care: July 25, 2015

July 25th 2015

This Week in Managed Care: July 25, 2015

This week Bristol-Myers Squibb's phase 3 nivolumab study ended early because renal cell carcinoma patients were experiencing significantly better overall survival, the American Society of Clinical Oncology called for the inclusion of more geriatric patients in trials, and Medicaid expansion states are finding more people enrolling than they planned.

July 24th 2015

Palliative Chemotherapy Can Worsen Quality of Life in End-Stage Cancer Patients

End-stage cancer patients who were in general the healthiest and most active displayed worse quality of life signs in their last week of life when they were given palliative chemotherapy and there were no benefits to overall survival.

July 24th 2015

Computational Approach Relates Gene Signatures With Cancer Outcomes

A study published in Nature Medicine has identified a gene signature that can predict cancer patient outcomes across a wide spectrum of malignancies.

July 24th 2015

Will Drug Costs Be the Big Political Issue of 2016?

Mary K. Caffrey

Recent surveys have found that public sentiment on drug costs runs high and crosses the political divide. A move this week by the nation's leading oncologists to rein in therapy pricing may be a sign that this is the breakthrough issue of the presidential campaign.

July 23rd 2015

Need for Palliative Care for Improved Performance at the End of Life

A study in JAMA Oncology has found that chemotherapy for patients with end-stage cancer was associated with worse quality of life near death while they still retained their ability to perform many life functions.

...

123 124 125 126 127 128 129 130 131

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions